Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multidisciplinary management of thymic carcinoma
    Journal Article

    Riely, G. J.; Huang, J.; Rimner, A.
    American Society of Clinical Oncology Educational Book (2012)

    Fulltext@MSK | Save
  • Relief of feedback inhibition of RTK and RAS signaling in V600E BRAF melanomas exposed to RAF inhibitors buffers their effects on signaling
    Meeting Abstract

    Pratilas, C. A.; Joseph, E. W.; Tadi, M.; Poulikakos, P. I.; Gabay, M.; Lito, P.; Wong, W.; DeStanchina, E.; Chandarlapaty, S.; Rosen, N.
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Novel and targeted therapies
    Book Section

    Zauderer, M. G.; Traina, T. A.; Lichtman, S. M.
    In Naeim, A.; Reuben, D. B.; Ganz, P. A. (Eds.) Management of Cancer in the Older Patient (2012)

    Fulltext@MSK | Save
  • The role of EGFR and KRAS mutations in locally advanced lung adenocarcinoma treated with definitive radiation therapy
    Meeting Abstract

    Rimner, A.; Wang, H.; Tsang, M.; Drilon, A.; Paik, P. K.; Hsu, M.; Zhang, Z.; Rosenzweig, K.; Wu, A. J.; Zakowski, M.
    Journal of Thoracic Oncology (2012)

    Fulltext@MSK | Save
  • Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Riely, G. J.; Evans, T. L.; Salgia, R.; Ou, S. I.; Gettinger, S. N.; Otterson, G. A.; Lanzalone, S.; Polli, A.; Shaw, A. T.
    Journal of Thoracic Oncology (2012)

    Fulltext@MSK | Save
  • Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma
    Journal Article

    Rosenzweig, K. E.; Zauderer, M. G.; Laser, B.; Krug, L. M.; Yorke, E.; Sima, C. S.; Rimner, A.; Flores, R.; Rusch, V.
    International Journal of Radiation Oncology, Biology, Physics (2012)

    Fulltext@MSK | Save
  • A large retrospective analysis of the activity of pemetrexed (PEM) in patients (patients) with ALK+ NSCLC before crizotinib (CRIZ)
    Meeting Abstract

    Scagliotti, G. V.; Kim, D. W.; Shaw, A. T.; Ou, S. H. I.; Riely, G. J.; Gettinger, N.; Besse, B.; Thomas, M.; Salgia, R.; Wilner, K.; more...
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • The role of EGFR and KRAS mutations in locally advanced lung adenocarcinoma treated with definitive radiation therapy
    Meeting Abstract

    Rimner, A.; Wang, H.; Tsang, M.; Drilon, A.; Paik, P. K.; Hsu, M.; Zhang, Z.; Rosenzweig, K. E.; Wu, A. J.; Zakowski, M. F.
    International Journal of Radiation Oncology, Biology, Physics (2012)

    Fulltext@MSK | Save
  • First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers
    Meeting Abstract

    Kris, M. G.; Mok, T.; Ou, S. H. I.; Martins, R. G.; Kim, D. W.; Goldberg, Z.; Zhang, H.; Taylor, I.; Letrent, S. P.; Jänne, P. A.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Results of a global phase II study with crizotinib in advanced ALK-positive non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Kim, D. W.; Ahn, M. J.; Shi, Y.; De Pas, T. M.; Yang, P. C.; Riely, G. J.; Crino, L.; Evans, T. L.; Liu, X.; Han, J. Y.; more...
    Annals of Oncology (2012)

    Fulltext@MSK | Save